CRISPR Approach Slows Duchenne in Mouse Study

The Penn Medicine technique boosts utrophin as a stand-in for missing dystrophin, a route that remains research-stage with no human trial timeline reported.

Updated on Nov. 3, 2026 in Biotech

Unlabeled glass tubes and a pipette rack on a white laboratory bench, with a microscope softly blurred in the background under cool window light. — Penn Medicine researchers used CRISPR gene editing to boost the protein utrophin in mice, slowing Duchenne muscular dystrophy in a preclinical study with no human trial reported. AI Illustration. Upload story photo >

Penn Medicine researchers identified a new use for CRISPR gene editing that slowed Duchenne muscular dystrophy in a preclinical model, in which a stand-in protein, utrophin, was boosted to compensate for missing dystrophin. The work is research-stage and has been tested in mice, not in patients.

Why it matters

Duchenne muscular dystrophy, which affects one in 5,000 males and typically leads to death, has few effective treatments, so a mechanism that bypasses the faulty gene is a notable shift in approach. Penn and the Children's Hospital of Philadelphia (CHOP) also reported a separate case in which personalized CRISPR editing was used on an infant, suggesting the field is moving toward bespoke gene therapies for rare diseases.

The Duchenne findings come from a preclinical study in mice, where boosting utrophin improved muscle function and microscopic tissue changes. The infant case documented one patient, and the source does not report outcomes beyond the initial six-month life expectancy, so neither result establishes a broader treatment effect.

The players

Penn Medicine

The University of Pennsylvania's medical enterprise, active in gene-editing research and the institution where the Duchenne study was conducted.

Children's Hospital of Philadelphia (CHOP)

A major pediatric research hospital that partnered with Penn to treat the infant with CPS1 deficiency using personalized CRISPR editing.

U.S. Food and Drug Administration (FDA)

The federal regulator that Penn worked with on a new protocol for regulatory approval of treatments for rarer diseases.

The details

Duchenne muscular dystrophy is caused by a gene that fails to produce enough functional dystrophin, a protein in muscle cells that stabilizes the plasma membrane and protects fibers during contraction. Researchers instead boosted utrophin, a related protein that can act as a stand-in for dystrophin. The technique combined two delivery systems already in use with CRISPR gene editing, a method for precisely altering DNA.

Last year: Penn Medicine and CHOP treated an infant with personalized CRISPR gene editing.

The Tech Race

Penn Medicine and CHOP are positioning CRISPR as a route to personalized treatment for rare genetic diseases, with the FDA protocol work aimed at making approvals feasible for conditions affecting small patient populations. The Duchenne result is a preclinical step, and its competitive standing relative to other dystrophy therapies is not described in the source.

Families affected by Duchenne or CPS1 deficiency may eventually have access to gene-editing treatments, but the source gives no availability, pricing, or approval dates for either approach. The Duchenne work remains in preclinical testing and is not an available treatment today.

The takeaway

Watch for whether the utrophin approach moves from mouse studies into human testing, a step that would show whether the mouse improvements carry over to patients. The FDA protocol Penn developed for rarer-disease treatments will also indicate how personalized gene therapies are reviewed going forward.